West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services, Inc., the largest biopharma employer in Massachusetts, has announced layoffs affecting 137 employees in its Cambridge facility. The layoffs are part of a restructuring effort aimed at streamlining operations and adapting to changing market conditions. The company has indicated that these job cuts are necessary to maintain competitiveness in the biopharmaceutical sector. The layoffs are set to take effect on October 1, 2023, as the company seeks to realign its workforce with its strategic goals. This move reflects broader trends in the industry as companies adjust to economic pressures.
West Pharmaceutical Services, Inc., a major pharmaceutical company based in New Jersey, has announced plans to lay off approximately 3,000 employees as part of a $3 billion cost savings initiative. This decision comes amid ongoing efforts to streamline operations and improve financial performance. The layoffs are part of a broader restructuring strategy aimed at enhancing efficiency and reducing operational costs. While specific dates for the layoffs have not been disclosed, the company is expected to implement these changes in the near future. The announcement reflects the challenges faced by the pharmaceutical industry and the need for companies to adapt to changing market conditions.
No one has shared a story from West Pharmaceutical Services, I yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.